Tags

urothelial carcinoma (UC)

#AUA14 - Differential gene expression in responsive versus recurrent non-muscle invasive high-grade urothelial carcinomas after induction BCG - Session Highlights

ORLANDO, FL USA (UroToday.com) - Although BCG remains the intravesical therapy of choice, after TURBT, for high-grade non-muscle invasive bladder carcinomas (NMIBC), a recurrence and progression rate of up to 40% occurs after induction treatment. BCG failure likely can be attributed, at least partially, to inherent tumoral characteristics.
Published May 18, 2014
Do we have biomarkers to predict response to neoadjuvant and adjuvant chemotherapy and immunotherapy in bladder cancer?

Radical cystectomy (RC) is the standard of care treatment of localized muscle-invasive bladder cancer (BC). However, about 50% of patients develop metastases within 2 years after cystectomy. Neoadjuvant cisplatin-based chemotherapy before cystectomy improves the overall survival (OS) in patients with muscle-invasive BC.
Published January 30, 2018
Emerging biomarkers and targeted therapies in urothelial carcinoma.

The use of immunotherapy has revolutionized the management of patients with locally advanced, unresectable, and metastatic urothelial carcinoma (UC); however, platinum-based chemotherapy remains a therapeutic cornerstone both in localized muscle-invasive and advanced UC.
Published August 6, 2018
Expert Commentary: Adjuvant chemotherapy in patients with urothelial carcinoma and adverse pathologic features receiving prior neoadjuvant chemotherapy and radical cystectomy.
Neoadjuvant chemotherapy is a standard of care for patients with cisplatin-eligible muscle-invasive urothelial carcinoma. For patients who do not receive neoadjuvant chemotherapy, there is evidence of a benefit associated with cisplatin-based adjuvant chemotherapy after radical cystectomy for patients with pT3/T4 and/or pN⁺ bladder cancer. It is unknown whether additional adjuvant chemotherapy is beneficial for patients with adverse pathological features after neoadjuvant chemotherapy and radical cystectomy.

Published September 2, 2017
Expert Commentary: Avelumab, an Anti–Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study.
Platinum-resistant urothelial carcinoma is a lethal disease. After a long period of therapeutic stagnation, the last two years have witnessed an explosion in the development of new second-line therapies.

Published August 10, 2017
Expert Commentary: Circulating Tumor Cells in Bladder and Upper Tract Urothelial Carcinoma
Circulating tumor cells (CTCs) are cancer cells shed from the tumor that enter the circulation. Isolating circulating tumor cells from urothelial carcinoma patients has several potential diagnostic, prognostic and predictive clinical applications but the available data has been inconclusive.

Published July 11, 2017
Expert Commentary: Neoadjuvant chemotherapy prior to radical cystectomy for muscle-invasive bladder cancer with variant histology.
Neoadjuvant chemotherapy is a standard of care for patients with urothelial muscle-invasive bladder cancer. Histologic variants of bladder cancer are less common but often clinically aggressive. Understanding whether neoadjuvant chemotherapy results in the same benefit in histological variants as in urothelial bladder cancer is crucial.

Published August 8, 2017
From the Desk of Evan Yu: “No…the ball game is not over...adjuvant trials of PD-1 and PD-L1 antibodies in urothelial carcinoma must go on!”
On May 10^th, 2017, a shocking thing happened. A trial that most everyone assumed was a slam-dunk for a phase 3 trial in metastatic or locally advanced urothelial carcinoma bounced off the rim, as it failed to meet its primary endpoint of overall survival. This trial utilized atezolizumab vs. a taxane in the prior platinum treated setting, with the intention of sealing the victory after atezolizumab gained accelerated FDA approval for response rate and durability of response for this patient population approximately a year ago.

Published May 18, 2017
Management of high-grade, non-muscle invasive urothelial carcinoma in a pre-pubertal patient with TURBT and intravesical BCG.

High-grade urothelial carcinoma (UC) of the bladder is rare in the pediatric population with no established guidelines for management. We treated a single female patient, 10 years of age, who was found to have high-grade, non-muscle invasive UC endoscopically and with intravesical BCG.
Published October 27, 2018
Molecular analysis of urothelial cancer cell lines for modeling tumor biology and drug response.

The utility of tumor-derived cell lines is dependent on their ability to recapitulate underlying genomic aberrations and primary tumor biology. Here, we sequenced the exomes of 25 bladder cancer (BCa) cell lines and compared mutations, copy number alterations (CNAs), gene expression and drug response to BCa patient profiles in The Cancer Genome Atlas (TCGA).

Published November 17, 2016
New targeted therapies in the management of urothelial carcinoma of the bladder, "Beyond the Abstract," by Philippe E. Spiess, MD, MSc, FACS, FRCS(C)

BERKELEY, CA (UroToday.com) - Urothelial carcinoma (UC), despite the myriad of treatment approaches and our progressively increasing knowledge into its disease processes, remains one of the most clinically challenging problems in modern health care.
Published June 19, 2014

E-Newsletters

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Tags

urothelial carcinoma (UC)

Free Daily and Weekly newsletters offered by content of interest

Login